Baseline Medication use in ADNI

Baseline Medication Use in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Noam Epstein, MD, MS Board Certified Neurologist Board Eligible Clinical Pharmacologist

Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Current AD Treatments ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Current MCI Treatments ,[object Object]

Current MCI Treatments ,[object Object],[object Object]

Polypharmacy in the Elderly ,[object Object],[object Object]

Polypharmacy and Adverse Effects ,[object Object],[object Object]

Beer’s List ,[object Object],[object Object]

ADNI Study Design (n=800) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Medication Use in ADNI ,[object Object],[object Object],[object Object]

Polypharmacy Histogram in ADNI

Top 10 Beer’s Medications in ADNI ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Polypharmacy in ADNI ,[object Object],[object Object],[object Object],[object Object]

MCI and AD Treatment in ADNI Treatment Number of Subjects MCI (n=400) AD (n=184) Donepezil 189 120(30%) 69(37%) Galantamine 30 16(4.0%) 14(7.6%) Rivastigmine 11 7 (1.7%) 4(2.2%) Memantine 21 8(0.1%) 13(7.1%) Donepezil and Memantine 88 33(8.3%) 55(30%) Galantamine and Memantine 13 2(0.5%) 11(6.0%) Rivastigmine and Memantine 7 1(0.3%) 6(3.2%)

Cholinesterase Treatment by Diagnosis ,[object Object],[object Object]

Off Label MCI Treatment in ADNI ,[object Object],[object Object],[object Object],[object Object]

Gender and Education are Associated with Cholinesterase Inhibitor Treatment of AD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Disease Severity is Associated with Memantine Treatment of AD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Recruitment in the MCI Group ,[object Object],[object Object],[object Object]

Age and Disease Severity are Associated with Cholinesterase Inhibitor Treatment of MCI ,[object Object],[object Object]

Gender, Education, Age and Disease Severity are Associated with Memantine Treatment of MCI ,[object Object],[object Object],[object Object],[object Object],[object Object]

Logistic Regression Models ,[object Object],[object Object],Previous analysis of the ADNI data [20] has shown that loss of hippocampal volume is the most sensitive MRI measure of disease progression from MCI to AD over one year. This data shows hippocampal volume is also negatively associated with baseline treatment in MCI. OR 95% CI P-value Age 0.959 0.930 0.989 0.0085 AVLT 0.969 0.945 0.994 0.0141 CDR-SB 1.453 1.137 1.856 0.0028 LHV 0.604 0.391 0.933 0.0231 OR 95% CI P-value Age 0.934 0.888 0.982 0.0079 Gender 2.577 1.106 6.001 0.0282 Education 1.157 1.020 1.312 0.0229 AVLT 0.913 0.868 0.960 0.0004 LHV 0.419 0.197 0.891 0.0239

AD Treatment Summary ,[object Object],[object Object],[object Object],[object Object]

MCI Treatment Summary ,[object Object],[object Object],[object Object],[object Object],[object Object]

Possible Explanations for the Treatment Differences by Gender ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object],[object Object]

References ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Acknowledgements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Baseline Medication use in ADNI

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

Similaire à Baseline Medication use in ADNI

Similaire à Baseline Medication use in ADNI (20)

Baseline Medication use in ADNI